The
Renaissance
Series
Expert exchange on disruptive drivers in healthcare
Providing Adelphi’s key clients with a unique opportunity to debate the most disruptive drivers of change in our industry with US and European senior thought leaders in healthcare.
The
Renaissance
Series
Expert exchange on disruptive drivers in healthcare.
Providing Adelphi’s key clients with a unique opportunity to debate the most disruptive drivers of change in our industry with US and European senior thought leaders in healthcare.
HERITAGE
LATEST TOPIC
PREVIOUS EVENTS
HERITAGE
LATEST TOPIC
PREVIOUS EVENTS
Join us in London: 16 May 2024
For the Latest Topic in the Renaissance Series
The Future of Pharma
Patients, Prevention & Medicine
Meeting the challenge of healthcare demand
TRANSFORMING VALUE
TRANSFORMING TRUST
PARIS 2022 / NEW JERSEY 2023
Join us in London: 16 May 2024
For the Latest Topic in the Renaissance Series
The Future of Pharma
Patients, Prevention & Medicine
Meeting the challenge of healthcare demand
TRANSFORMING VALUE
TRANSFORMING TRUST
PARIS 2022 / NEW JERSEY 2023
The Renaissance Heritage
“Adelphi Renaissance has been going for 17 years. We launched it on our 20th anniversary as a company. We wanted to plough something back into the healthcare industry that we serve, and we came up with the idea of Renaissance. So what is Renaissance?…
Renaissance provides a platform for senior decision makers to trade knowledge on hot topics. It brings together esteemed people both as speakers and panels in a meeting setting to actually air and discuss those hot topics of the day and hopefully to progress them. Over the years we have covered 8 different topics and 19 forums. On each topic we usually do one meeting in Europe and one in the United States. We involve a fairly select audience and usually we have between 20 and 40 guests in addition to the speakers. I am proud to say we always get absolutely fantastic speakers.
Please take a look at this website for the outputs from previous meetings and contact us for more information.”
Stuart Cooper, CEO, Adelphi Group
The Renaissance Heritage
“Adelphi Renaissance has been going for 17 years. We launched it on our 20th anniversary as a company. We wanted to plough something back into the healthcare industry that we serve, and we came up with the idea of Renaissance. So what is Renaissance?…
Renaissance provides a platform for senior decision makers to trade knowledge on hot topics. It brings together esteemed people both as speakers and panels in a meeting setting to actually air and discuss those hot topics of the day and hopefully to progress them. Over the years we have covered 8 different topics and 19 forums. On each topic we usually do one meeting in Europe and one in the United States. We involve a fairly select audience and usually we have between 20 and 40 guests in addition to the speakers. I am proud to say we always get absolutely fantastic speakers.
Please take a look at this website for the outputs from previous meetings and contact us for more information.”
Stuart Cooper, CEO, Adelphi Group
Outstanding Faculty
Each Adelphi Renaissance forum has its own unique expert faculty, who are passionate about the topic, representing a range of perspectives from academia, the medical profession, pharma industry, patients, regulatory and payer bodies.
Outstanding Faculty
Each Adelphi Renaissance forum has its own unique expert faculty, who are passionate about the topic, representing a range of perspectives from academia, the medical profession, pharma industry, patients, regulatory and payer bodies.
Latest topic
The Future of Pharma
Patients, Prevention & Medicine
Meeting the challenge of healthcare demand
This Renaissance event will explore the complex challenge of preventative strategies for all of us across healthcare, and in particular the future role of pharma companies and increasingly active patient groups as the focus shifts.
Renaissance Events
One day thought leadership forums
- Hear the views of opinion formers representing the physician, payer, patient and pharma perspective.
- Reflect on your own company strategy through informed discussion with senior decision makers.
- Experience an environment of regulatory and commercial excellence.
- Trade knowledge in a joint effort to define best practice in critical decision and development areas.
Latest topic
The Future of Pharma
Patients, Prevention & Medicine
Meeting the challenge of healthcare demand
Across many countries we are seeing a shift in focus towards preventative health, to help avoid serious disease or to delay the progression to more complex conditions, in response to chronic demands on healthcare.
This Renaissance event will explore the complex challenge of preventative strategies for all of us across healthcare, and in particular the future role of pharma companies and increasingly active patient groups as the focus shifts.
Renaissance Events
One day thought leadership forums
- Hear the views of opinion formers representing the physician, payer, patient and pharma perspective.
- Reflect on your own company strategy through informed discussion with senior decision makers.
- Experience an environment of regulatory and commercial excellence.
- Trade knowledge in a joint effort to define best practice in critical decision and development areas.
Previous Renaissance Topics
Transforming Value Transforming Trust
PARIS 2022 / NEW JERSEY 2023
Striving for TRANSFORMATIONAL VALUE:
Are we ready for radical change?
2018-2020
PATIENTCENTRICITY:
Defining our Role
2016-2017
REAL WORLD EVIDENCE:
The New Standard of Proof
2014-2015
PERSONALISED MEDICINE:
Moving from Promise to Practice
2011-2013
THE PATIENT EXPERIENCE IN CONTEXT:
Understanding its Impact on Future Pharma Strategies
2008-2010
Previous Renaissance Topics
Transforming Value Transforming Trust
2022
Striving for TRANSFORMATIONAL VALUE:
Are we ready for radical change?
2018-2020
PATIENTCENTRICITY:
Defining our Role
2016-2017
REAL WORLD EVIDENCE:
The New Standard of Proof
2014-2015
PERSONALISED MEDICINE:
Moving from Promise to Practice
2011-2013
THE PATIENT EXPERIENCE IN CONTEXT:
Understanding its Impact on Future Pharma Strategies
2008-2010
